Grants for Public housing authorities - Food and Nutrition

This funding opportunity supports research using advanced cellular models to investigate HIV interactions with tissues related to diabetes, digestive, and kidney diseases, particularly focusing on HIV persistence, latency, and related health issues.

This funding opportunity is designed to support clinical centers conducting research on the development of Type 1 diabetes following episodes of acute pancreatitis, focusing on understanding its causes, progression, and risk factors in a diverse population.

This funding opportunity provides financial support to organizations that will help improve diabetes prevention and management for underserved populations by offering expertise, training, and resources to enhance health equity.

This funding opportunity provides financial support to public agencies and nonprofit organizations to deliver essential primary health care services to underserved communities across the United States.

This grant provides funding for innovative, interdisciplinary research projects that aim to advance understanding and treatment of diseases related to diabetes, digestive disorders, liver diseases, metabolic and nutritional disorders, kidney and urologic diseases, and obesity.

This funding opportunity provides financial support to state and local governments, educational institutions, nonprofits, and other organizations to implement strategies that promote better nutrition and physical activity, ultimately reducing chronic disease risks in their communities.

This funding opportunity supports U.S. institutions in developing educational programs that provide undergraduate and early-stage graduate students with hands-on research experiences in kidney technology development and entrepreneurship.

This funding opportunity is designed to support researchers investigating the connections between HIV/AIDS and various health issues related to diabetes, digestive, kidney, and metabolic diseases, particularly focusing on the complications and social factors affecting people living with HIV.

Not available

This grant provides funding to organizations that promote vaccine confidence and health equity through partnerships and educational outreach, particularly targeting underserved populations across the United States.

The main objective of this NOFO is to foster development and testing of technologies adaptable to aging-related changes in older adults (aged 65 years or older) with T1D to improve diabetes management and quality of life. Older adults may have increased vulnerability to hypoglycemia, cognitive impairment and/or multiple co-morbidities which may affect the risks and benefits of these technologies in this population. Projects will be funded to a) develop and test new technologies and b) to adapt and test existing technologies. It is expected that aging-adaptive diabetes technologies that address barriers for use among older adults with T1D will improve usability, adoption and adherence decreasing the risk of hypoglycemia (and hypoglycemia unawareness) while enhancing glycemic control, facilitating better diabetes management, and improving quality of life for these individuals and their caregivers.

This funding opportunity supports independent research projects in health-related fields for a wide range of eligible applicants, including universities, nonprofits, and small businesses, without allowing clinical trials.

This funding opportunity provides substantial financial support to higher education institutions and nonprofit organizations to establish collaborative centers that advance research and resources for HIV/AIDS.

The Food Safety Education Fund grants program, administered by the Michigan Department of Agriculture & Rural Development (MDARD), is designed to enhance food safety throughout Michigan. Funded by assessments on licensed food establishments, the program aligns with a mission to protect public health by providing critical food safety training and education. This initiative directly supports the broader goal of ensuring a safe food supply for all Michigan residents. The foundation's strategic priority is to prevent foodborne illness through proactive education and the empowerment of various stakeholders within the food system. The program primarily targets two key beneficiary groups: Michigan consumers and food service establishment employees, as well as agents of the director who enforce food regulations (e.g., local health department sanitarians and MDARD food safety inspectors). The impact goal is to improve food safety knowledge and practices among these groups, ultimately reducing the incidence of foodborne illnesses. Eligibility is restricted to Michigan governmental and non-profit organizations and entities, ensuring that the grants support organizations deeply embedded in community health and public service. Producers, marketers, processors, and growers are explicitly excluded to maintain the program's focus on education and training. For the 2024-2025 grant cycle, up to $365,600 is available, with a specific allocation of $242,500 for consumer food safety education and $114,100 for food service establishment employees and regulatory agents. This demonstrates a clear prioritization of widespread public education while also fortifying the knowledge base of those directly involved in food handling and enforcement. The grant duration is typically one year, though multi-year proposals are considered on an individual basis, contingent on future funding availability. Proposals should specifically avoid requesting funding for routine or required training, such as HACCP or ServSafe certification, emphasizing a focus on innovative and supplementary educational initiatives. Proposals are evaluated based on several key criteria, including goals and objectives to improve food safety, assessment of statewide need and audience, measurable outcomes, potential for partnering with other organizations, inclusion of matching funds, and opportunities to build upon previously funded projects. These selection criteria reflect the program's theory of change, which posits that strategic partnerships, evidence-based interventions, and quantifiable results are essential for achieving sustainable improvements in food safety. The expected outcomes include a more informed public, better-trained food service professionals, and more effective enforcement of food safety regulations, all contributing to a safer food environment across Michigan.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.

This funding opportunity supports researchers in discovering and validating new targets for developing safe and effective pain treatments with minimal side effects and low addiction risk.

This funding opportunity provides financial support for organizations involved in child nutrition programs in Idaho to upgrade their technology systems and improve operational efficiency.

This program provides funding to support businesses and organizations involved in processing, storing, and distributing locally produced food in Michigan, helping to strengthen the state's food supply chain.

This Funding Opportunity Announcement (FOA) seeks innovative grant applications in nonmalignant hematology research that will steer the field in new directions. Applications to this FOA should propose proof of principle research that is tightly focused into one specific aim, which can be accomplished within a 1-3 year project period, and is directed at validating novel concepts and approaches that promise to open new pathways for discovery.The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung, and Blood Institute (NHLBI), and the National Institute on Aging (NIA) have joined together to build research activities in nonmalignant hematology. This Funding Opportunity Announcement (FOA) is intended to promote innovative research projects in nonmalignant hematology that explore high impact and new directions of inquiry. While each Institute shares interests in nonmalignant hematology research, they also bring different perspectives, thereby expanding the scope of the SHINE II program beyond a single Institute's research mission. This "New Directions in Hematology Research (SHINE-II)" program invites investigator-initiated grant applications for basic or early translational, proof of principle research projects that are tightly focused and directed at validating novel concepts and approaches that promise to advance new pathways for discovery. This program may include clinical research involving human subjects that is directed at understanding disease pathogenesis and prognosis. Research applications submitted under this FOA should be more limited in scope (single aim with sub-aims, as appropriate) and duration (1-3 years) than typical R01 grant applications. The SHINE-II FOA seeks specifically to promote and support new directions of research in their early stages. Applications submitted to this FOA should include preliminary data that support the conceptual basis of the research proposed and the technical approaches to be used. Moreover, while research applications submitted under this FOA are expected to be more limited in scope and shorter in duration than typical R01 applications, achievement of the research objective(s) proposed should validate novel pathways of discovery and provide the basis for future high impact research endeavors. Principal areas of interest for this collaborative FOA include: (1) hematopoietic stem cell biology, (2) lineage fate determinants, (3) aging-related immune dysfunction and lymphocyte biology, (4) myeloid cell biology, and myelopoiesis, (5) platelet biology and dysfunction, (6) erythroid cell biology and erythropoiesis, (7) the molecular biology of heme and hemoglobin, (8) acquired and congenital disorders of red blood cell production and survival leading to chronic anemia or bone marrow failure, (9) and the uptake, utilization, storage, and transport of iron in health and disease. Inquiries to Scientific/Research staff prior to submission of an application to this FOA are strongly encouraged to discuss programmatic relevance and potential time tables for funding (see below, Section VII. Agency Contacts). The limited scope and shorter duration of the SHINE II R01 are not optimal for Early Stage Investigators (ESIs) and New Investigators (NIs), who should contact Scientific/Research staff prior to submission of an application to this FOA.